Investegate | Company Announcement
Investegate announcements from Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
Source: investegate.co.uk
📰 Sponsored Level News
Sponsored Level News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Sponsored Level. Real-time updates on events, politics, business and more.
Ipsen updates on QM-1114 regulatory process
PARIS, FRANCE, 3 October 2023 – Ipsen announced today that its partner Galderma has confirmed receipt from the FDA of a Complete Response Letter related to its Biologics License Application for...
Source: marketscreener.com
Ipsen updates on QM-1114 regulatory process - Ipsen (OTC:IPSEY)
PARIS, FRANCE, 3 October 2023 – Ipsen ((Euronext: IPN, OTC:IPSEY) announced today that its partner Galderma has confirmed receipt from the FDA of a Complete Response Letter related to its Biologics License Application
United Kingdom France General United States Arbitral Tribunal Of The International Chamber Complete Response Letter Biologics License Application
Source: benzinga.com
Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet - Ipsen (OTC:IPSEY)
PARIS, FRANCE, 1 September 2023 – Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Christelle Huguet as Executive Vice President, Head of
Source: benzinga.com
Ipsen announces change in R&D leadership: Howard Mayer to
 PARIS, FRANCE, 1 September 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment...
Source: globenewswire.com
US FDA approves Ipsen's SohonosTM (palovarotene) capsules,
Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia...
Source: globenewswire.com
US FDA approves Ipsen's SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia ossificans progressiva FOP impacts about 400... -Today at 03:33 pm- MarketScreener
Source: marketscreener.com
Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
Paris, France: 27 July 2023Ipsen , a global specialty-care biopharmaceutical company, presents today its financial results for the first half of 2023. H1 2023 total sales up by 7.4% at CER1 , with...
Source: marketscreener.com
Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
Positive opinion from Committee for Medicinal Products for Human Use based on Bylvay Phase III ASSERT clinical-trial data in Alagille syndrome Negative opinion from Committee for Orphan Medicinal...
Source: marketscreener.com
Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
Positive opinion from Committee for Medicinal Products for Human Use based on Bylvay Phase III ASSERT clinical-trial data in Alagille syndrome Negative opinion from Committee for Orphan Medicinal...
Source: marketscreener.com